Mereo Biopharma Group Plc (0A9G) Stock Statistics & Valuation Metrics
Total Valuation
Mereo Biopharma Group Plc has a market cap or net worth of $46.21M. The enterprise value is $21.97M.
- Market Cap
- $46.21M
- Enterprise Value
- $21.97M
Share Statistics
Mereo Biopharma Group Plc has 159,690,980 shares outstanding. The number of shares has decreased by -2.65% in one year.
- Shares Outstanding
- 159,690,980
- Owned by Insiders
- 0.81%
- Owned by Institutions
- 0.07%
Financial Efficiency
Mereo Biopharma Group Plc’s return on equity (ROE) is -1.02 and return on invested capital (ROIC) is -91.49%.
- Return on Equity (ROE)
- -1.02
- Return on Assets (ROA)
- -0.91
- Return on Invested Capital (ROIC)
- -91.49%
- Return on Capital Employed (ROCE)
- -0.92
- Revenue Per Employee
- 12.82K
- Profits Per Employee
- -1.07M
- Employee Count
- 39
- Asset Turnover
- 0.01
- Inventory Turnover
- 0.00
Valuation Ratios
The current PE Ratio of Mereo Biopharma Group Plc is -1.59. Mereo Biopharma Group Plc’s PEG ratio is -0.03.
- PE Ratio
- -1.59
- PS Ratio
- 0.00
- PB Ratio
- 1.62
- Price to FCF
- -1.82
- Price to Operating Cash Flow
- -1.84
- PEG Ratio
- -0.03
Income Statement
In the last 12 months, Mereo Biopharma Group Plc had revenue of 500.00K and earned -41.88M in profits. Earnings per share was -0.26.
- Revenue
- 500.00K
- Gross Profit
- 367.00K
- Operating Income
- -38.26M
- Pretax Income
- -41.88M
- Net Income
- -41.88M
- EBITDA
- -40.47M
- Earnings Per Share (EPS)
- -0.26
Cash Flow
In the last 12 months, operating cash flow was -25.35M and capital expenditures -1,521, giving a free cash flow of -25.35M billion.
- Operating Cash Flow
- -25.35M
- Free Cash Flow
- -25.35M
- Free Cash Flow per Share
- -0.16
Dividends & Yields
Mereo Biopharma Group Plc pays an annual dividend of ―, resulting in a dividend yield of ―
- Dividend Per Share
- ―
- Dividend Yield
- ―
- Payout Ratio
- N/A
- Free Cash Flow Yield
- -54.83%
- Earnings Yield
- -60.35%
Stock Price Statistics
- Beta
- 0.61
- 52-Week Price Change
- -84.86%
- 50-Day Moving Average
- 0.31
- 200-Day Moving Average
- 0.33
- Relative Strength Index (RSI)
- 44.21
- Average Volume (3m)
- 123.57K
Important Dates
Mereo Biopharma Group Plc upcoming earnings date is Nov 17, 2026, TBA (Not Confirmed).
- Last Earnings Date
- Aug 11, 2026
- Next Earnings Date
- Nov 17, 2026
- Ex-Dividend Date
- ―
Financial Position
Mereo Biopharma Group Plc as a current ratio of 10.46, with Debt / Equity ratio of 0.49%
- Current Ratio
- 10.46
- Quick Ratio
- 10.46
- Debt to Market Cap
- 0.00
- Net Debt to EBITDA
- 1.01
- Interest Coverage Ratio
- -150.03
Taxes
In the past 12 months, Mereo Biopharma Group Plc has paid 0 in taxes.
- Income Tax
- 0
- Effective Tax Rate
- 0.00
Enterprise Valuation
Mereo Biopharma Group Plc EV to EBITDA ratio is -0.52, with an EV/FCF ratio of -0.68.
- EV to Sales
- 0.00
- EV to EBITDA
- -0.52
- EV to Free Cash Flow
- -0.68
- EV to Operating Cash Flow
- -0.68
Balance Sheet
Mereo Biopharma Group Plc has $30.12M in cash and marketable securities with $1.03M in debt, giving a net cash position of $29.09M billion.
- Cash & Marketable Securities
- $30.12M
- Total Debt
- $1.03M
- Net Cash
- $29.09M
- Net Cash Per Share
- $0.18
- Tangible Book Value Per Share
- $0.18
Margins
Gross margin is 0.00%, with operating margin of 0.00%, and net profit margin of 0.00%.
- Gross Margin
- 0.00%
- Operating Margin
- 0.00%
- Pretax Margin
- 0.00%
- Net Profit Margin
- 0.00%
- EBITDA Margin
- 0.00%
- EBIT Margin
- 0.00%
Analyst Forecast
The average price target for Mereo Biopharma Group Plc is $3.00, which is 11.43% higher than the current price. The consensus rating is Neutral
- Price Target
- $3.00
- Price Target Upside
- 938.06% Upside
- Analyst Consensus
- Neutral
- Analyst Count
- 4
- Revenue Growth Forecast
- ―
- EPS Growth Forecast
- ―
Scores
- Smart Score
- 4
- AI Score
- ―